Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma

 

 Buy Article Permissions and Reprints

Abstract

Cutaneous squamous cell carcinoma (cSCC) and melanoma encompass the majority of all malignant skin cancers. There has been an increase in their incidence globally in recent decades. In cases of high-risk, unresectable, or metastatic disease; or when patient factors or preferences limit the availability of conventional surgery or radiotherapy; or a systemic therapy is often warranted. Our improved understanding of the molecular and immune pathogenesis underlying tumor growth and development has been critical in advancing cancer therapeutics. Over the past several years, several new systemic agents have been approved for both diseases. The role of cytotoxic chemotherapy is gradually waning with the introduction of targeted therapy and immunotherapy. In this article, we review the current and relevant literature and evidence of cytotoxic chemotherapy, targeted therapy, and immune checkpoint inhibitors in the adjuvant and neoadjuvant settings for cSCC and melanoma. Additionally, we describe their role in the unresectable or metastatic disease setting.

^∗ Drs. Ma and Haring contributed equally to the development of this manuscript.

• References

• 1 NCCN Clinical Practice Guidelines in Oncology. NCCN guidelines: squamous cell skin carcinoma. Available at: https://www.nccn.org/patients/guidelines/content/PDF/squamous_cell-patient.pdf . Accessed March 5, 2020
  PubMedGoogle Scholar
• 2 NCCN Clinical Practice Guidelines in Oncology NCCN guidelines: cutaneous melanoma. Available at: https://www.nccn.org/patients/guidelines/content/PDF/melanoma-patient.pdf . Accessed March 5, 2020
  PubMedGoogle Scholar
• 3 Gandhi SA, Kampp J. Skin cancer epidemiology, detection, and management. Med Clin North Am 2015; 99 (06) 1323-1335
  CrossrefPubMedGoogle Scholar
• 4 Noronha V, Joshi A, Patil VM. , et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 2018; 36 (11) 1064-1072
  CrossrefPubMedGoogle Scholar
• 5 Maubec E, Petrow P, Scheer-Senyarich I. , et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29 (25) 3419-3426
  CrossrefPubMedGoogle Scholar
• 6 Foote MC, McGrath M, Guminski A. , et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014; 25 (10) 2047-2052
  CrossrefPubMedGoogle Scholar
• 7 Vermorken JB, Mesia R, Rivera F. , et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
  CrossrefPubMedGoogle Scholar
• 8 Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 2018; 29 (01) 71-83
  PubMedGoogle Scholar
• 9 Tosoni A, Franceschi E, Pasquini E. , et al. Immunotherapy in head and neck cancer: evidence and perspectives. Immunotherapy 2017; 9 (16) 1351-1358
  CrossrefPubMedGoogle Scholar
• 10 Weber J, Mandala M, Del Vecchio M. , et al; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377 (19) 1824-1835
  CrossrefPubMedGoogle Scholar
• 11 Schachter J, Ribas A, Long GV. , et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390 (10105): 1853-1862
  CrossrefPubMedGoogle Scholar
• 12 Porceddu SV, Bressel M, Poulsen MG. , et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol 2018; 36 (13) 1275-1283
  CrossrefPubMedGoogle Scholar
• 13 Kim J, Park MK, Li W-Q, Qureshi AA, Cho E. Association of vitamin A intake with cutaneous squamous cell carcinoma risk in the United States. JAMA Dermatol 2019
  PubMedGoogle Scholar
• 14 Brewster AM, Lee JJ, Clayman GL. , et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 2007; 25 (15) 1974-1978
  CrossrefPubMedGoogle Scholar
• 15 Sadek H, Azli N, Wendling JL. , et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990; 66 (08) 1692-1696
  CrossrefPubMedGoogle Scholar
• 16 Guthrie Jr TH, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990; 8 (02) 342-346
  CrossrefPubMedGoogle Scholar
• 17 Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol 1999; 22 (01) 32-34
  CrossrefPubMedGoogle Scholar
• 18 Reigneau M, Robert C, Routier E. , et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol 2015; 173 (02) 527-534
  CrossrefPubMedGoogle Scholar
• 19 Jenni D, Karpova MB, Mühleisen B. , et al. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open 2016; 1 (01) e000003
  CrossrefPubMedGoogle Scholar
• 20 William Jr WN, Feng L, Ferrarotto R. , et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol 2017; 77 (06) 1110-1113.e2
  CrossrefPubMedGoogle Scholar
• 21 Lewis CM, Glisson BS, Feng L. , et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18 (05) 1435-1446
  CrossrefPubMedGoogle Scholar
• 22 Shin DM, Glisson BS, Khuri FR. , et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002; 20 (02) 364-370
  CrossrefPubMedGoogle Scholar
• 23 Gold KA, Kies MS, William Jr WN, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial. Cancer 2018; 124 (10) 2169-2173
  CrossrefPubMedGoogle Scholar
• 24 Migden MR, Rischin D, Schmults CD. , et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379 (04) 341-351
  CrossrefPubMedGoogle Scholar
• 25 Morton DL, Thompson JF, Cochran AJ. , et al; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370 (07) 599-609
  CrossrefPubMedGoogle Scholar
• 26 Faries MB, Thompson JF, Cochran AJ. , et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376 (23) 2211-2222
  CrossrefPubMedGoogle Scholar
• 27 Wilson MA, Schuchter LM. Chemotherapy for melanoma. Cancer Treat Res 2016; 167: 209-229
  PubMedGoogle Scholar
• 28 Middleton MR, Grob JJ, Aaronson N. , et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18 (01) 158-166
  CrossrefPubMedGoogle Scholar
• 29 Chapman PB, Robert C, Larkin J. , et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 2017; 28 (10) 2581-2587
  CrossrefPubMedGoogle Scholar
• 30 Flaherty KT, Robert C, Hersey P. , et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367 (02) 107-114
  CrossrefPubMedGoogle Scholar
• 31 Larkin J, Ascierto PA, Dréno B. , et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371 (20) 1867-1876
  CrossrefPubMedGoogle Scholar
• 32 Dummer R, Ascierto PA, Gogas HJ. , et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19 (05) 603-615
  CrossrefPubMedGoogle Scholar
• 33 Robert C, Karaszewska B, Schachter J. , et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372 (01) 30-39
  CrossrefPubMedGoogle Scholar
• 34 Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 (Suppl. 01) S11-S14
  PubMedGoogle Scholar
• 35 Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14 (01) 7-17
  CrossrefPubMedGoogle Scholar
• 36 Hodi FS, O'Day SJ, McDermott DF. , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (08) 711-723
  CrossrefPubMedGoogle Scholar
• 37 Eggermont AMM, Chiarion-Sileni V, Grob JJ. , et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer 2019; 119: 1-10
  CrossrefPubMedGoogle Scholar
• 38 Robert C, Long GV, Brady B. , et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372 (04) 320-330
  CrossrefPubMedGoogle Scholar
• 39 Eggermont AMM, Blank CU, Mandala M. , et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378 (19) 1789-1801
  CrossrefPubMedGoogle Scholar
• 40 Tarhini AA, Lee SJ, Hodi S, Cohen GI, Hamid O. United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma. J Clin Oncol 2019; 37 (15) 9504-9504
  CrossrefPubMedGoogle Scholar
• 41 Long GV, Hauschild A, Santinami M. , et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017; 377 (19) 1813-1823
  CrossrefPubMedGoogle Scholar
• 42 Amaria RN, Prieto PA, Tetzlaff MT. , et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018; 19 (02) 181-193
  CrossrefPubMedGoogle Scholar
• 43 Amaria RN, Reddy SM, Tawbi HA. , et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018; 24 (11) 1649-1654
  CrossrefPubMedGoogle Scholar
• 44 Huang AC, Orlowski RJ, Xu X. , et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019; 25 (03) 454-461
  CrossrefPubMedGoogle Scholar
• 45 Larkin J, Chiarion-Sileni V, Gonzalez R. , et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381 (16) 1535-1546
  CrossrefPubMedGoogle Scholar